A randomized, double-blind, placebo-controlled, parallel groups, multicenter trial investigating the efficacy and safety of FE 999049 in controlled ovarian stimulation in women aged 35-42 years undergoing assisted reproductive technology - Recombinant FSH Investigation in the Treatment of Infertility with ART (RITA-2)
A clinical trial investigating the safety and evaluating how well a study drug works in women having difficulty becoming pregnant
Sponsor: Ferring Pharmaceuticals, Inc.
Enrolling: Female Patients Only
Study Length: 18 Months
IRB Number: AAAS1253
U.S. Govt. ID: NCT03738618
Contact: Eric Forman, MD, HCLD: 646-756-8282 / ef2572@cumc.columbia.edu
Additional Study Information: This clinical research study is for women between the ages of 35 and 42 years who are having difficulty becoming pregnant and who would like to receive treatment within an assisted reproductive technology (ART) program in order to become pregnant. The purpose of this research study is to test the safety and effectiveness of an investigation drug called FE 999049, which is a new recombinant follicle-stimulating hormone (FSH) product for ovarian stimulation in women undergoing ART.
This study is closed
Investigator
Eric Forman, MD, HCLD
Do You Qualify?
Are you a woman aged 35-42 years? Yes No
Have you undergone no more than one previous controlled ovarian stimulation? Yes No
Do you have a regular menstrual cycles of 24-35 days (both inclusive)? Yes No
Do you have a known history of recurrent miscarriage? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Eric Forman, MD, HCLD
ef2572@cumc.columbia.edu
646-756-8282
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE